Harmony Biosciences Holdings

Epygenix Therapeutics is a biopharmaceutical company dedicated to discovering and developing precision medicines for rare and severe forms of genetic epilepsy, with a primary focus on Dravet syndrome (DS). DS is an intractable form of epilepsy that starts in infancy and has limited effective treatment options, significantly impacting the quality of life for patients and their families. The company aims to address this unmet medical need by creating safe and efficacious drugs using its EPX series of compounds, discovered through genetic zebrafish models.

Zynerba Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company based in Devon, Pennsylvania, established in 2007. The company is focused on developing innovative transdermal cannabinoid therapies aimed at addressing rare and near-rare neuropsychiatric disorders. Its lead product, Zygel, is a transdermal cannabidiol gel designed for consistent and controlled delivery of cannabinoids, which is currently undergoing Phase II clinical trials for various conditions, including developmental and epileptic encephalopathies, autism spectrum disorder, behavioral and emotional symptoms of 22q11.2 deletion syndrome, and fragile X syndrome. Zynerba also has additional therapeutic candidates leveraging proprietary transdermal technologies, with the potential to reduce adverse effects associated with traditional oral dosing. The company aims to provide effective treatment options for patients with significant unmet medical needs.